For a consultation with one of our physicians: 212-414-8812.
Active Surveillance is a Viable Alternative for Men with Limited Amount of Low-Grade Prostate Cancer

With the recent controversy surrounding the topic of the use of surgery for the treatment of prostate cancer, the concept of active Surveillance has become increasingly appealing. Active surveillance involves the selective monitoring of men with low-risk prostate cancer, allowing them to avoid unnecessary treatments. The rationale behind active surveillance is that many men with low-risk prostate cancer will not develop symptoms or die from their disease. The goal is to provide these men the option of deferring treatment until symptoms arise or disease progression is detected.

Dr. William K. Oh, MD, Chief of Urology at The Deane Center, is an advocate of active surveillance as a viable treatment option for men with low-risk prostate cancer. Dr. Oh believes that active surveillance allows patients to avoid the potential side effects and complications of surgery and radiation, while still ensuring that they receive appropriate treatment if needed.

One of Dr. Oh's primary research interests is the development of novel agents in a neo-adjuvant setting. This involves a treatment approach where a patient is given a therapeutic agent, such as chemotherapy or immunotherapy, prior to surgery or radiation. Dr. Oh's work in this area has led to the development of new drugs that can improve the outcomes of patients with prostate cancer.

In addition to his research, Dr. Oh is also working on the development of a six-board of care that will be implemented at The Deane Center. The six-board approach is designed to enhance the quality of care for patients with prostate cancer and improve their overall experience.


Dr. Oh is also a member of the editorial board of the Journal of Hematology and Oncology. He is actively involved in the field of prostate cancer research and has made significant contributions to the understanding of the biology and treatment of this disease.

Dr. Oh is a leader in the field of prostate cancer research and has made significant contributions to the understanding of the biology and treatment of this disease. He is actively involved in clinical trials aimed at improving the outcomes of patients with prostate cancer.

Dr. Oh is also involved in community outreach and education. He is a frequent speaker at prostate cancer education and support meetings for survivors and families. He is also a mentor to young urologists and is committed to the training of the next generation of urologists.

William K. Oh, MD, Mra with Deane Center

The Deane Center Quarterly

For Information about Deane Center programs and clinical trials: 212-241-0445.

For a consultation with one of our physicians: 212-241-4812.

Simon J. Hall, MD, Named Kyung Hyun Kim, MD Chair in Urology at 2009 Mount Sinai Convocation

Simon J. Hall, MD, was named the chair of the Department of Urology at Mount Sinai Hospital, effective immediately. Dr. Hall will lead the department, which is one of the largest and most respected in the country.

Dr. Hall is a leader in the field of prostate cancer research and has made significant contributions to the understanding of the biology and treatment of this disease. He is actively involved in clinical trials aimed at improving the outcomes of patients with prostate cancer.

Dr. Hall is also involved in community outreach and education. He is a frequent speaker at prostate cancer education and support meetings for survivors and families. He is also a mentor to young urologists and is committed to the training of the next generation of urologists.

Simon J. Hall, MD, Mra with Deane Center